Seres Therapeutics Inc (NASDAQ:MCRB) insider John G. Aunins sold 14,279 shares of the company’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $8.57, for a total value of $122,371.03. Following the completion of the sale, the insider now owns 170,206 shares in the company, valued at $1,458,665.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of MCRB stock opened at $9.55 on Thursday. The company has a current ratio of 3.60, a quick ratio of 3.60 and a debt-to-equity ratio of 0.85. The firm has a market cap of $361.00 million, a PE ratio of -4.32 and a beta of 0.52. Seres Therapeutics Inc has a 52 week low of $6.65 and a 52 week high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.06. The company had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $3.00 million. Seres Therapeutics had a negative return on equity of 150.44% and a negative net margin of 277.79%. equities analysts predict that Seres Therapeutics Inc will post -2.53 EPS for the current year.
A number of brokerages have weighed in on MCRB. BidaskClub upgraded Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday. ValuEngine upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Finally, Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. Seres Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $17.89.
Several hedge funds have recently made changes to their positions in the company. Alps Advisors Inc. grew its holdings in shares of Seres Therapeutics by 21.0% during the first quarter. Alps Advisors Inc. now owns 54,359 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 9,448 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Seres Therapeutics during the fourth quarter worth $143,000. Wells Fargo & Company MN grew its holdings in shares of Seres Therapeutics by 107.2% during the fourth quarter. Wells Fargo & Company MN now owns 29,183 shares of the biotechnology company’s stock worth $296,000 after purchasing an additional 15,097 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Seres Therapeutics by 72.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 49,530 shares of the biotechnology company’s stock worth $502,000 after purchasing an additional 20,839 shares during the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of Seres Therapeutics by 153.6% during the fourth quarter. Two Sigma Advisers LP now owns 35,500 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 21,500 shares during the last quarter. Institutional investors own 79.53% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.